Fig. 1: NFIC is overexpressed in AML.
a Immunoblot showing NFIC (~56KDa) protein expression in subcellular fractions of FAB-M1 AML patient blasts. NFIC overexpressing HEK-293T cells (Supplementary Fig S1b) were used as a positive control to determine NFIC expression. GAPDH and Histone 1 (H1) were used as loading controls for cytosolic (C) and nuclear (N) protein respectively. b Immunoblot of NFIC protein expression in AML patient blasts compared to CD34+ HSPCs and normal human bone marrow (BM) in nuclear lysates in a second independent patient cohort to that of samples previously analyzed by MS. c NFIC protein expression in AML cell lines. d NFIC mRNA expression (Log2) in Normal hematopoietic subsets and in different AML subtypes (For complete description of AML subtypes and normal blood cells refer to Bloodspot data set for BloodPool: AML samples with normal cells) and normal hematopoietic cells analyzed using BloodSpot and the following data sets: GSE13159, GSE15434, GSE61804, GSE14468, The Cancer Genome Atlas (TCGA) and GSE42519 (for normal blood cells) [20,21,22,23,24,25,26,27,28] Horizontal markers indicate median expression intensities. Tukey’s test was used to analyze the level of statistical significance of individual AML subtype compared to normal HSC where ***p < 0.001, ****p < 0.001 and ‘ns’ is non-significant.
